Tricyclic antidepressant: Difference between revisions
imported>Robert Badgett m (→Mechanism of action: Made links) |
imported>Robert Badgett No edit summary |
||
| Line 11: | Line 11: | ||
==Mechanism of action== | ==Mechanism of action== | ||
[[Depression]] may be due to the monoamine-deficiency hypothesis, which is a "deficiency in [[serotonin]] or [[norepinephrine]] neurotransmission in the brain."<ref name="pmid18172175">{{cite journal |author=Belmaker RH, Agam G |title=Major depressive disorder |journal=N. Engl. J. Med. |volume=358 |issue=1 |pages=55–68 |year=2008 |pmid=18172175 |doi=10.1056/NEJMra073096|url=http://content.nejm.org/cgi/content/full/358/1/55}}</ref> | [[Depression]] may be due to the monoamine-deficiency hypothesis, which is a "deficiency in [[serotonin]] or [[norepinephrine]] neurotransmission in the brain."<ref name="pmid18172175">{{cite journal |author=Belmaker RH, Agam G |title=Major depressive disorder |journal=N. Engl. J. Med. |volume=358 |issue=1 |pages=55–68 |year=2008 |pmid=18172175 |doi=10.1056/NEJMra073096|url=http://content.nejm.org/cgi/content/full/358/1/55}}</ref> | ||
By blocking the ''reuptake'' of [[norepinephrine]] and [[serotonin]], tricyclics may overcome the mono-amine deficiency.<ref name="isbn0-07-145153-6">{{cite book |author=Katzung, Bertram G. |authorlink= |editor= |others= |title=Basic and Clinical Pharmacology |edition=10th |chapter=Antidepressant Agents |chapterurl= |language= |publisher=McGraw-Hill Medical Publishing Division |location=New York |year=2006 |origyear= |pages= |quote= |isbn=0-07-145153-6 |oclc= |doi= |url=http://www.accessmedicine.com/resourceTOC.aspx?resourceID=16 |accessdate=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 08:56, 19 December 2008
In medicine and pharmacology, tricyclic antidepressants are adrenergic uptake inhibitors that "contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system."[1]
Classification
Tertiary amine tricyclics
Older tricyclics include amitriptyline, doxepin, and imipramine have a tertiary-amine side chain block both serotonin and norepinephrine and increase anticholinergic drug toxicity.[2]
Secondary amine tricyclics
Secondary amine tricyclics include desipramine, nortriptyline, and others have less anticholinergic drug toxicity.
Mechanism of action
Depression may be due to the monoamine-deficiency hypothesis, which is a "deficiency in serotonin or norepinephrine neurotransmission in the brain."[3]
By blocking the reuptake of norepinephrine and serotonin, tricyclics may overcome the mono-amine deficiency.[4]
References
- ↑ Anonymous (2024), Tricyclic antidepressant (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ (2006) “Antidepressant Agents”, Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th. New York: McGraw-Hill. ISBN 0-07-142280-3.
- ↑ Belmaker RH, Agam G (2008). "Major depressive disorder". N. Engl. J. Med. 358 (1): 55–68. DOI:10.1056/NEJMra073096. PMID 18172175. Research Blogging.
- ↑ Katzung, Bertram G. (2006). “Antidepressant Agents”, Basic and Clinical Pharmacology, 10th. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6.